← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
51	51 Cellectis CLLS $111M	40	+3	+8%	$137M
52	52 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	40	-9	-18%	$3.85M
53	53 Neurogene NGNE $479M	39	-10	-20%	$384M
54	54 uniQure QURE $1.56B	39	-12	-24%	$46.8M
55	55 Fulgent Genetics FLGT $587M	37	0	0%	$38.1M
56	56 CRISPR Therapeutics CRSP $4.98B	35	+9	+35%	$211M
57	57 Opus Genetics IRD $337M	33	+2	+6%	$7.3M
58	58 Pluri PLUR $11.9M	29	-2	-6%	$4.5M
59	59 DELISTED Carisma Therapeutics CARM	27	0	0%	$5.26M
60	60 CareDx CDNA $3.45B	27	-4	-13%	$33.4M
61	61 DELISTED BRAINSTORM CELL THERAPUTC BCLI	26	-1	-4%	$4.65M
62	62 Ocugen OCGN $276M	25	+2	+9%	$19.2M
63	63 Capricor Therapeutics CAPR $423M	21	+1	+5%	$3.01M
64	HTGM 64 DELISTED HTG Molecular Diagnostics, Inc. Common Stock HTGM	21	+8	+62%	$20.6M
65	ONCS 65 DELISTED OncoSec Medical Incorporated ONCS	21	-5	-19%	$2.41M
66	66 ProQR Therapeutics PRQR $205M	20	-3	-13%	$45M
67	PTE 67 DELISTED PolarityTE, Inc. Common Stock PTE	18	+6	+50%	$3.76M
68	68 Imunon IMNN $5.95M	17	-6	-26%	$1.09M
69	69 DELISTED BioLife Solutions BLFS	15	-4	-21%	$558K
70	70 Mesoblast MESO $1.81B	13	-3	-19%	$22.1M
71	71 Enlivex Ltd ENLV $4.46M	11	-2	-15%	$404K
72	72 Eterna Therapeutics ERNA $2.53M	8	0	0%	$6.21M
73	CYAD 73 DELISTED Celyad Oncology SA American Depositary Shares CYAD	6	0	0%	$10.5M
74	74 Marker Therapeutics MRKR $15.3M	6	+1	+20%	$163K
75	75 ARK Genomic Revolution ETF ARKG $2.09B	4	-1	-20%	$689K